Overview
Corporate Video
Executive Management
Board of Directors
Board Committees
Corporate Governance
Scientific Advisory Board
Platform
Platform Overview
Publications
Pipeline
Pipeline Overview
SAB-195: CDI
SAB-176: Influenza
SAB-185: COVID-19
Partnering
Patients
C. diff Patient Information
Influenza
COVID-19
Expanded Access Policy
Media
News & Press Releases
Events
Presentations
Publications
Shareholder Services
Overview
SEC Filings
Stock Quote & Chart
Board of Directors
Corporate Governance
Board Committees
Analyst Coverage
RSS Feeds
Contact Us
Overview
Corporate Video
Executive Management
Board of Directors
Board Committees
Corporate Governance
Scientific Advisory Board
Platform
Platform Overview
Publications
Pipeline
Pipeline Overview
SAB-195: CDI
SAB-176: Influenza
SAB-185: COVID-19
Partnering
Patients
C. diff Patient Information
Influenza
COVID-19
Expanded Access Policy
Media
News & Press Releases
Events
Presentations
Publications
Shareholder Services
Overview
SEC Filings
Stock Quote & Chart
Board of Directors
Corporate Governance
Board Committees
Analyst Coverage
RSS Feeds
Contact Us
Home
>
News
October 13, 2021
Introduction to SAB’s Unique DiversitAb™ Immunotherapy Platform
RSS
All
|
News
|
Press Release
|
Events
SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021
October 6, 2021
SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19
October 4, 2021
SAB Biotherapeutics Appoints Russell Beyer Chief Financial Officer
September 28, 2021
SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19
September 24, 2021
Big Cypress Acquisition Corp Announces Special Meeting of Stockholders to Approve Business Combination with SAB Biotherapeutics
September 23, 2021
SAB Biotherapeutics Awarded Additional $60.5M from BARDA and U.S. Department of Defense for Rapid Response Capability and Advancing SAB-185 for Treatment of COVID-19
September 22, 2021
SAB Biotherapeutics Announces Completion of Enrollment in Phase 2a Challenge Trial of SAB-176 for the Treatment of Seasonal Influenza
September 15, 2021
SAB Biotherapeutics to Present at Upcoming September Virtual Investor Conferences
September 8, 2021
SAB Biotherapeutics Announces Nonclinical Data Demonstrating SAB-185 Potently Neutralizes Delta and Lambda SARS-CoV-2 Variants
August 11, 2021
SAB Biotherapeutics to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021
July 9, 2021
SAB Biotherapeutics Announces Publication of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS-CoV-2 Variants
July 8, 2021
Next